DK0702673T3 - Benz(b)azepin-2,5-dioner anvendelige ved behandlingen af neurodegenerative forstyrrelser - Google Patents

Benz(b)azepin-2,5-dioner anvendelige ved behandlingen af neurodegenerative forstyrrelser

Info

Publication number
DK0702673T3
DK0702673T3 DK94917115T DK94917115T DK0702673T3 DK 0702673 T3 DK0702673 T3 DK 0702673T3 DK 94917115 T DK94917115 T DK 94917115T DK 94917115 T DK94917115 T DK 94917115T DK 0702673 T3 DK0702673 T3 DK 0702673T3
Authority
DK
Denmark
Prior art keywords
benz
treatment
neurodegenerative disorders
azepine
dione useful
Prior art date
Application number
DK94917115T
Other languages
Danish (da)
English (en)
Inventor
Marc Jerome Chapdelaine
Timothy Wayne Davenport
Charles David Mclaren
Jeffrey Alan Mckinney
Laura Enid Garcia-Davenport
Paul Francis Jackson
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Application granted granted Critical
Publication of DK0702673T3 publication Critical patent/DK0702673T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK94917115T 1993-06-10 1994-06-09 Benz(b)azepin-2,5-dioner anvendelige ved behandlingen af neurodegenerative forstyrrelser DK0702673T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939311948A GB9311948D0 (en) 1993-06-10 1993-06-10 Substituted nitrogen heterocycles
PCT/GB1994/001243 WO1994029275A1 (en) 1993-06-10 1994-06-09 Benz(b)azepine-2,5-diones useful in the treatment of neurodegenerative disorders

Publications (1)

Publication Number Publication Date
DK0702673T3 true DK0702673T3 (da) 1998-11-23

Family

ID=10736919

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94917115T DK0702673T3 (da) 1993-06-10 1994-06-09 Benz(b)azepin-2,5-dioner anvendelige ved behandlingen af neurodegenerative forstyrrelser

Country Status (15)

Country Link
US (2) US5502048A (de)
EP (1) EP0702673B1 (de)
JP (1) JPH08511513A (de)
AT (1) ATE163409T1 (de)
AU (1) AU684789B2 (de)
CA (1) CA2161251A1 (de)
DE (1) DE69408668T2 (de)
DK (1) DK0702673T3 (de)
ES (1) ES2112546T3 (de)
GB (2) GB9311948D0 (de)
HU (1) HU9501709D0 (de)
IL (1) IL109968A (de)
NZ (1) NZ266855A (de)
TW (1) TW282459B (de)
WO (1) WO1994029275A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9212308D0 (en) * 1992-06-10 1992-07-22 Ici Plc Therapeutic compositions
GB9311948D0 (en) * 1993-06-10 1993-07-28 Zeneca Ltd Substituted nitrogen heterocycles
US5801168A (en) * 1994-06-09 1998-09-01 Zeneca Limited Substituted nitrogen heterocycles
US5977125A (en) 1994-10-31 1999-11-02 Eisai Co., Ltd. Mono-or polyenic carboxylic acid derivatives
US5476933A (en) * 1994-11-16 1995-12-19 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Azepine synthesis via a diels-alder reaction
KR19990087585A (ko) * 1996-03-08 1999-12-27 돈 리사 로얄 신경학적 활성제로서의 아졸로벤즈아제핀 유도체
US6211235B1 (en) 1996-11-22 2001-04-03 Elan Pharmaceuticals, Inc. Compounds for inhibiting β-amyloid peptide release and/or its synthesis
US6191166B1 (en) 1997-11-21 2001-02-20 Elan Pharmaceuticals, Inc. Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis
US6683075B1 (en) 1996-12-23 2004-01-27 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use
US6635632B1 (en) * 1996-12-23 2003-10-21 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6552013B1 (en) 1998-06-22 2003-04-22 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6528505B1 (en) 1998-06-22 2003-03-04 Elan Pharmaceuticals, Inc. Cyclic amino acid compounds pharmaceutical compositions comprising same and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6509331B1 (en) 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6569851B1 (en) * 1998-06-22 2003-05-27 Elan Pharmaceutials, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6774125B2 (en) * 1998-06-22 2004-08-10 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US20050192265A1 (en) * 2003-03-20 2005-09-01 Thompson Richard C. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
GB0900641D0 (en) * 2009-01-15 2009-02-25 Syngenta Ltd Novel herbicides
GB0901835D0 (en) * 2009-02-04 2009-03-11 Syngenta Ltd Novel herbicides

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1340334A (en) * 1970-07-06 1973-12-12 Rees A H Synthesis of benzazetropolones and hence of kynurenic acids
JPS5129522B2 (de) * 1972-07-13 1976-08-26
JPS5520970B2 (de) * 1972-07-15 1980-06-06
EP0072352B1 (de) * 1981-08-11 1986-03-05 Ciba-Geigy Ag Benzazepin-2-one, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese Verbindungen enthalten, sowie die Verbindungen zur therapeutischen Verwendung
US4410520A (en) * 1981-11-09 1983-10-18 Ciba-Geigy Corporation 3-Amino-[1]-benzazepin-2-one-1-alkanoic acids
US4473575A (en) * 1982-07-19 1984-09-25 Ciba-Geigy Corporation 3-Amino-(1)-benzazepin-2-one-1-alkanoic acids
US4575503A (en) * 1983-02-10 1986-03-11 Ciba-Geigy Corporation 3-Amino-[1]-benzazepin-2-one-1-alkanoic acids
US4477446A (en) * 1983-07-01 1984-10-16 Usv Pharmaceutical Corporation 1-Benzazepines and their pharmaceutical uses
DE3416695A1 (de) * 1984-05-05 1985-11-07 Bayer Ag, 5090 Leverkusen Amidinohydrazone von tetralin-, chromon-, thiochromon- und tretrahydrochinolin-derivaten, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
US5322943A (en) * 1985-09-12 1994-06-21 The Upjohn Company Piperazine compounds which are substituted
US5266684A (en) * 1988-05-02 1993-11-30 The Reagents Of The University Of California Peptide mixtures
US4885364A (en) * 1988-11-23 1989-12-05 E. R. Squibb & Sons, Inc. Resolution process for benzazepine intermediates
PT93943A (pt) * 1989-05-05 1991-02-08 Searle & Co Processo para a preparacao de composicoes contendo compostos indole-2-carboxilato para tratamento de perturbacoes do snc
US5229413A (en) * 1989-05-05 1993-07-20 G. D. Searle & Co. Compositions containing indole-2-carboxylate compounds for treatment of CNS disorders
US5026700A (en) * 1989-05-16 1991-06-25 Merrell Dow Pharmaceuticals Certain quinolines and thienopyridines as excitatory amino acid antagonists
CA2016465A1 (en) * 1989-06-02 1990-12-02 Zola Phillip Horovitz Method for preventing or treating anxiety employing a calcium channel blocker
JPH0334977A (ja) * 1989-06-29 1991-02-14 Yoshitomi Pharmaceut Ind Ltd イミダゾリルベンゾラクタム化合物
DK0450097T3 (da) * 1989-10-20 1996-05-20 Otsuka Pharma Co Ltd Benzoheterocykliske forbindelser
US5622832A (en) * 1990-02-28 1997-04-22 Genetics Institute, Inc. Arachidonic acid releasing phospholipase A2 enzyme and methods of use
US5051442A (en) * 1990-04-25 1991-09-24 Merrell Dow Pharmaceuticals Inc. 3-indolyl thioacetate derivatives and NMDA receptor antagonistic use thereof
US5182366A (en) * 1990-05-15 1993-01-26 Huebner Verena D Controlled synthesis of peptide mixtures using mixed resins
DE69113115T2 (de) * 1990-05-31 1996-06-13 Merck Sharp & Dohme Dioxo-tetrahydrochinolinderivate.
GB9022785D0 (en) * 1990-10-19 1990-12-05 Merck Sharp & Dohme Therapeutic agents
US5189054A (en) * 1990-11-02 1993-02-23 Merrell Dow Pharmaceuticals Inc. 3-amidoindolyl derivatives and pharmaceutical compositions thereof
CA2054339C (en) * 1990-11-02 2002-12-24 Francesco G. Salituro 3-amidoindolyl derivatives
GB9026389D0 (en) * 1990-12-05 1991-01-23 Merck Sharp & Dohme Therapeutic agents
GB9100028D0 (en) * 1991-01-02 1991-02-20 Ici Plc Compounds
WO1992013535A1 (en) * 1991-02-06 1992-08-20 Research Corporation Technologies, Inc. Anticonvulsant substituted quinazolones
US5330768A (en) * 1991-07-05 1994-07-19 Massachusetts Institute Of Technology Controlled drug delivery using polymer/pluronic blends
EP0542689B1 (de) * 1991-11-15 1998-09-23 Phafag Aktiengesellschaft Verwendung von 1-(aminoalkyl)-3-Quinoxalin-2-on Derivaten zur Herstellung von neuroprotektiven Mitteln
JP2712144B2 (ja) * 1992-02-06 1998-02-10 田辺製薬株式会社 血小板凝集抑制組成物
GB9206266D0 (en) * 1992-03-23 1992-05-06 Merck Sharp & Dohme Therapeutic agents
GB9212308D0 (en) * 1992-06-10 1992-07-22 Ici Plc Therapeutic compositions
KR100304017B1 (ko) * 1992-06-22 2001-11-22 추후제출 글리신수용체길항물질및이의용도
CA2098446A1 (en) * 1992-09-30 1994-03-31 Eckard Weber 2,5-dihydro-2,5-dioxo-1h-azepines and 2,5-dihydro-2-oxo-1h-azepines and the use thereof as excitatory amino acid and glycine receptor antagonists
US5514690A (en) * 1992-11-17 1996-05-07 E. R. Squibb & Sons, Inc. Aminocarbonyl (thiocarbonyl) and cyanoguanidine derivatives of quinoline and indoline
US5428069A (en) * 1993-01-11 1995-06-27 The United States Of America As Represented By The Department Of Health & Human Services Treating cognition with, aminocyclopropanecarboxylic derivatives
AU6246394A (en) * 1993-02-22 1994-09-14 Cavalier Pharmaceuticals, Inc. Use of heparin to inhibit interleukin-8
ZA941290B (en) * 1993-02-26 1995-08-25 Res Dev Foundation Combination cisplatin/tamoxifen therapy for human cancers
GB9311948D0 (en) * 1993-06-10 1993-07-28 Zeneca Ltd Substituted nitrogen heterocycles

Also Published As

Publication number Publication date
US5502048A (en) 1996-03-26
IL109968A0 (en) 1994-10-07
CA2161251A1 (en) 1994-12-22
US5656626A (en) 1997-08-12
GB9311948D0 (en) 1993-07-28
HU9501709D0 (en) 1996-03-28
JPH08511513A (ja) 1996-12-03
AU684789B2 (en) 1998-01-08
DE69408668T2 (de) 1998-07-09
EP0702673B1 (de) 1998-02-25
EP0702673A1 (de) 1996-03-27
TW282459B (de) 1996-08-01
ES2112546T3 (es) 1998-04-01
NZ266855A (en) 1997-09-22
WO1994029275A1 (en) 1994-12-22
AU6854494A (en) 1995-01-03
ATE163409T1 (de) 1998-03-15
DE69408668D1 (de) 1998-04-02
IL109968A (en) 1999-11-30
GB9411242D0 (en) 1994-07-27

Similar Documents

Publication Publication Date Title
DK0702673T3 (da) Benz(b)azepin-2,5-dioner anvendelige ved behandlingen af neurodegenerative forstyrrelser
PL326671A1 (en) Derivatives of 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxathiazol-2(3h)-one for application as ligands of 5-ht4 or h3 receptor
BG103548A (en) Vitronectine receptor antagonists
WO1999047131A3 (en) Combination of a gaba-a alpha 5 inverse agonist and an acetylcholinesterase inhibitor
AU1977997A (en) Non-peptidyl vasopressin v1a antagonists
FI943941A0 (fi) CCK-reseptoriantagonisteina käyttökelpoiset bentsodiatsepiinijohdannaiset
ZA969610B (en) Tricyclic herbicidal heterocycles.
DE69330754D1 (de) 2,5-DIOXO-2,5-DIHYDRO-1H-BENZ[b]AZEPINE ALS NMDA REZEPTOR ANTAGONISTEN
MY127686A (en) Monofluoroalkyl derivatives
AU7458994A (en) 1,5-benzodiazepine derivatives useful as cck or gastrin antagonists
FR2637796B1 (fr) Charniere pour abattant de w.c.
IS1961B (is) Notkun 1-(2-naft-2-ýletýl)-4(3-tríflúorómetýlfenýl)-1,2,3,6-tetrahýdrópýridíns til gerðar lyfja tilþess að meðhöndla hliðarstrengjahersli
NO974310D0 (no) Låseinnretning, særlig for håndbagasje
FI960836A7 (fi) Bentsodiatsepiiniyhdisteet, jotka ovat käyttökelpoisia CCK- tai gastriiniantagonisteina
FR2711747B1 (fr) Elément de fixation pour pièces de construction en céramique.
NZ329839A (en) Combination of a compound which inhibits acetylcholinesterase or exhibits muscarinergic action and a compound which increases the endogenous extracellular adenosine level for treating dementia
PL328228A1 (en) 1-(pyrazol-3-yl-ethyl)-4-(indol-3-yl)-piperidines as agents influencing the central nervous system
ATE221066T1 (de) Heterozyklische verbindungen
AU3476599A (en) Indol-3-yl-cyclohexyl amine derivatives for the treatment of depression (5-ht1 receptor antagonists)
ZA963192B (en) Process for making heterocyclic compounds.
FR2714637B1 (fr) Cellule arrière fonctionnelle monobloc, pour véhicules de série et les véhicules ainsi équipés.
FR2802965B1 (fr) Serrure pour conteneur de dechets
FR2769658B1 (fr) Barillet de serrure pour serrure de securite
MX9707187A (es) Derivados de imidazopiridina.
AU7228994A (en) 1,5-benzodiazepine derivatives useful as cck or gastrin antagonists